Semaglutide: A GLP-1 Medication for Diabetes and Chronic Weight Management
Semaglutide is a prescription medication in a class called glucagon-like peptide-1 receptor agonists, or GLP-1 medications. It works by mimicking a naturally occurring intestinal hormone that helps regulate blood sugar, appetite, and digestion. Depending on the FDA-approved product and the individual patient’s clinical needs, semaglutide may be prescribed for type 2 diabetes, chronic weight management, and certain cardiovascular or kidney-risk reduction indications. [61][73]
Semaglutide is not a stimulant and does not “burn fat” directly. It can improve blood-sugar control by increasing insulin release when blood glucose is elevated, reducing glucagon signaling, slowing stomach emptying, and helping some people feel full sooner or for longer after meals. These effects can support reduced calorie intake when the medication is used alongside an appropriate nutrition, activity, and medical-care plan.
FDA-Approved Uses
FDA-approved semaglutide products have different indications, formulations, and doses. For example, certain products are approved to improve blood-sugar control in adults with type 2 diabetes, while others are approved for chronic weight management in eligible adults and adolescents when used with a reduced-calorie eating plan and increased physical activity. Specific cardiovascular and kidney risk-reduction indications may also apply to selected adults with type 2 diabetes and chronic kidney disease. [61][66][68]
- Improvement of blood-sugar control in type 2 diabetes
- Chronic weight management for appropriately eligible patients
- Reduction of certain cardiovascular risks in selected populations
- Reduction of kidney-disease progression risk in certain adults with type 2 diabetes and chronic kidney disease
Dosage and Treatment Approach
Semaglutide dosing depends on the specific FDA-approved product and its intended use. Injectable semaglutide is generally administered once weekly, but treatment is usually started at a lower dose and increased gradually according to the product label and the prescriber’s instructions. Gradual dose escalation may improve tolerability, especially gastrointestinal side effects.
Do not use a general dosing schedule from a website, social media post, or another patient’s prescription. Never change the dose, use the medication more often than directed, or combine semaglutide with another GLP-1 receptor agonist unless specifically instructed by a qualified prescriber.
Common Side Effects
The most common side effects are gastrointestinal and may include nausea, vomiting, diarrhea, constipation, abdominal pain, indigestion, or decreased appetite. Some people may also experience headache, fatigue, dizziness, or injection-site reactions. Side effects can be more noticeable during dose increases and should be discussed with a healthcare professional if persistent or severe. [70]
Important Safety Information
Semaglutide has a boxed warning regarding thyroid C-cell tumors observed in rodents. It is contraindicated for people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. It should also be used cautiously in people with a history of pancreatitis, gallbladder disease, significant gastrointestinal disease, diabetic retinopathy, or kidney problems. [63][65]
Seek prompt medical attention for severe or persistent abdominal pain, symptoms of dehydration, repeated vomiting, signs of an allergic reaction, vision changes, or symptoms of low blood sugar—especially when semaglutide is used with insulin or certain diabetes medications.
Compounded Semaglutide Notice
FDA-approved semaglutide products are not the same as compounded products. Compounded drugs are not FDA-approved and do not undergo FDA review for safety, effectiveness, or manufacturing quality before dispensing. The FDA has reported adverse events, including hospitalizations, related to dosing errors with some compounded semaglutide products, particularly multi-dose vials that require patients to measure doses with syringes. [62][64]